To verify whether mast cell-derived IL-6 promotes BPH-1 cells proliferation through STAT3/Cyclin D1 signaling pathway, we then adopted an interruption approach to treat BPH-1 cells by using anti-IL-6 neutralizing antibody. The gene discussed is STAT3; the disease is benign prostatic hyperplasia.